- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Overlap Neoplasms, Chronic Neutrophilic Leukemia
- Interventions
- Momelotinib, Azacitidine
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 5,570
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C Virus Infection
- Interventions
- SOF/VEL/VOX
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • Rialto, California + 12 more
- Conditions
- Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
- Interventions
- [11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan
- Drug
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Gemcitabine, ACR-368
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Glaucoma
- Interventions
- (Cosopt®, prostaglandin)
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Chronic Low Back Pain, Negative Affectivity
- Interventions
- Antidepressant, Enhanced Fear Avoidance Rehabilitation
- Drug · Other
- Lead sponsor
- Ajay Wasan, MD, Msc
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania
- Conditions
- Non-small Cell Lung Cancer, Carcinoma, NSCLC
- Interventions
- Ensartinib, Durvalumab
- Drug
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- biphasic insulin aspart, insulin glargine
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Vestavia Hills, Alabama + 59 more
- Conditions
- Urinary Tract Infections, Cystitis
- Interventions
- Sulopenem etzadroxil/probenecid, Amoxicillin/clavulanate
- Drug
- Lead sponsor
- Iterum Therapeutics, International Limited
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 2,229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 167
- States / cities
- Cullman, Alabama • Saraland, Alabama • Sheffield, Alabama + 126 more
- Conditions
- Renal Impairment
- Interventions
- PF-07321332/ritonavir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 5
- States / cities
- Tustin, California • Miami, Florida • Tampa, Florida + 1 more
- Conditions
- Healthy Volunteers
- Interventions
- [11c] LAAM, Ritonavir, Efavirenz
- Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
- Interventions
- TNG456, abemaciclib
- Drug
- Lead sponsor
- Tango Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 15
- States / cities
- Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more
- Conditions
- Relapsed/Refractory B-Cell Lymphoma
- Interventions
- FT522, Rituximab, Cyclophosphamide, Fludarabine, Bendamustine
- Drug
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Detroit, Michigan • Minneapolis, Minnesota + 4 more
- Conditions
- Kidney Transplantation
- Interventions
- Tacrolimus + Ketoconazole, Then Tacrolimus alone, Tacrolimus alone, Then Tacrolimus + Ketoconazole
- Drug
- Lead sponsor
- Sony Tuteja
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Solid Tumor, Unspecified, Adult
- Interventions
- Rucaparib, Irinotecan
- Drug
- Lead sponsor
- Pamela Munster
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Stroke, Cerebrovascular Accident, Hemiparesis
- Interventions
- Armodafinil, Placebo
- Drug
- Lead sponsor
- Burke Rehabilitation Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- White Plains, New York
- Conditions
- Chronic Obstructive Pulmonary Disease, Sleep Disorders
- Interventions
- salmeterol-fluticasone
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 40 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HIV Infections
- Interventions
- Sulfamethoxazole-Trimethoprim, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1990
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- RAD001, LBH589, Doublet (RAD001 and LBH589)
- Drug
- Lead sponsor
- Anne Beaven, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Diabetes, Diabetes Mellitus, Type 2
- Interventions
- insulin degludec
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 45
- States / cities
- Huntsville, Alabama • Goodyear, Arizona • Mesa, Arizona + 40 more
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 298 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- Abacavir sulfate
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Greenbrae, California • Los Angeles, California • San Francisco, California + 5 more
- Conditions
- Heroin Dependence, Substance-Related Disorders
- Interventions
- Buprenorphine/naloxone
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 1997
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Methicillin-resistant Staphylococcus Aureus, Skin Infection
- Interventions
- TMP-SMX, DOXY
- Drug
- Lead sponsor
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Other
- Eligibility
- 9 Years to 85 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Sylmar, California • Torrance, California • St Louis, Missouri